Bladder Cancer Clinical Trial
Official title:
The Difference of Two Year Recurrence Rate According to Anesthetic Method During Transurethral Resection of Bladder Mass in Patients With Non-muscle Invasive Bladder Cancer: Prospective, Randomized, Clinical Phase II Study
The investigators compare the recurrence rate difference between two years after transurethral resection of the bladder tumor according to the method of anesthesia. Anesthetic methods are general anesthesia and spinal anesthesia. Assessment of recurrence is assessed by bladder endoscopy, CT, and pathological examination of surgical specimens.
1. Research Background Most of the bladder cancer (approximately 85%) has histologic
features of urothelial carcinoma. Approximately 75% of the patients initially diagnosed
as non-invasive bladder cancer (stage I, CIS) or submucosal stage T1 -muscle invasive
bladder cancer - NMIBC). However, it has been reported that about 60% to 70% of patients
experience recurrence and 20% to 30% of relapsed cancers require radical cystectomy or
chemotherapy It is known to progress to high-grade or high grade cancer.
There are studies that involve surgical factors such as volatile anesthetics, narcotic
analgesics, anti-body temperature, blood transfusion, and cancer recurrence. Minimizing
the use of volatile anesthetics and narcotic analgesics reduces spinal anesthesia before
and after surgery, It has been reported that there is a correlation with maintenance of
immune cell function
2. Research hypothesis and purpose The aim of this study was to evaluate the recurrence
rate, recurrence - free survival rate, and recurrence - free survival rate of non -
muscle invasive bladder carcinoma in patients undergoing bladder resection.
3. Research Method
- Preoperative screening: Physical examination, Blood test, CT urography, Urine
analysis, Urine culture, Urine cytology, Cystoscopy. Enforced
- Randomization on the day before surgery: 289 patients were randomly assigned to a
spinal anesthesia group and a general anesthesia group 1: 1.
Urine analysis, urine culture, urine cytology, and cystoscopy were performed every 3 months
up to 2 years postoperatively. CT urography performed once a year
- Follow-up procedure: Follow-up procedure according to bladder cancer standard.
4. Observation items, clinical examination items and observational examination methods
- Screening: CT urography, Urine analysis, Urine culture, Urine cytology, Cystoscopy.
Observe
- Follow up: Urine analysis, Urine culture, Urine cytology, Cystoscopy every 3 months
after the operation, CT urography every year
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06034015 -
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04235764 -
En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
|
||
Completed |
NCT02371447 -
VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04081246 -
Transurethral Modified En Bloc Resection For Large Bladder Tumours.
|
N/A | |
Recruiting |
NCT06059547 -
Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer
|
Phase 2 | |
Terminated |
NCT04779489 -
Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer
|
N/A | |
Not yet recruiting |
NCT04493489 -
Propranolol Adjuvant Treatment of Bladder Cancer
|
Phase 2 | |
Completed |
NCT03520231 -
Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases
|
Phase 2 | |
Recruiting |
NCT04537221 -
Nordic Cystectomy Study III - Transfusion
|
||
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Completed |
NCT01955408 -
Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment
|
N/A | |
Completed |
NCT04487457 -
Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
|
||
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05562791 -
A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer
|
Phase 1 | |
Completed |
NCT00199849 -
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
|
Phase 1 | |
Completed |
NCT02781428 -
To Detect the Sensitivity of the UroMark Assay
|
||
Recruiting |
NCT04738630 -
Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
|
Phase 2 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 | |
Active, not recruiting |
NCT03978624 -
Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer
|
Phase 2 | |
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A |